Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer

The study is a prospective randomized interventional study including patients with advanced non-small cell lung cancer, receiving immunotherapy, with the aim of optimizing treatment monitoring. The study aims to investigate the clinical utility of liquid biopsy monitoring in order to reduce the numbers of inefficient treatments and needless toxicity - and to explore the cost-effectiveness and cost-utility of introducing liquid biopsy monitoring in daily clinical practice.

Trial Details

NCT ID
NCT05889247
Phase
NA
Sponsor
Zealand University Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Circulating tumor DNA treatment monitoring
Locations (sample)
  • Hillerød, Region H, Denmark|55.92791,12.30081
  • Næstved, Region Sjælland, Denmark|55.22992,11.76092
  • Roskilde, Region Sjælland, Denmark|55.64152,12.08035
  • Aalborg, Denmark|57.048,9.9187
  • Vejle, Denmark|55.70927,9.5357

Key Eligibility Criteria

  • Newly diagnosed, histologically verified, Non-Small Cell Lung Cancer (NSCLC)
  • Advanced or locally advanced disease without curative intended treatment options
  • Age \> 18 years
  • Eastern Cooperative Oncology Group (ECOG) score of Performance Status (PS) 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →